$0.09 EPS Expected for PDL BioPharma (PDLI), Cowen Group Decreased By $2.55 Million Its Metlife (Call) (MET) Stake

July 17, 2017 - By Nellie Frank

Cowen Group Inc decreased Metlife Inc (Call) (MET) stake by 87.45% reported in 2016Q4 SEC filing. Cowen Group Inc sold 48,100 shares as Metlife Inc (Call) (MET)’s stock declined 4.70%. The Cowen Group Inc holds 6,900 shares with $372,000 value, down from 55,000 last quarter. Metlife Inc (Call) now has $59.02B valuation. The stock declined 0.22% or $0.12 reaching $55.22 per share. About 2.66 million shares traded. Metlife Inc (NYSE:MET) has risen 13.92% since July 17, 2016 and is uptrending. It has underperformed by 2.78% the S&P500.

Analysts expect PDL BioPharma Inc (NASDAQ:PDLI) to report $0.09 EPS on August, 3 after the close.They anticipate $0.00 EPS change or 0.00% from last quarter’s $0.09 EPS. PDLI’s profit would be $14.58 million giving it 6.69 P/E if the $0.09 EPS is correct. After having $0.08 EPS previously, PDL BioPharma Inc’s analysts see 12.50% EPS growth. About 929,786 shares traded. PDL BioPharma Inc (NASDAQ:PDLI) has declined 26.03% since July 17, 2016 and is downtrending. It has underperformed by 42.73% the S&P500.

Investors sentiment decreased to 0.93 in Q4 2016. Its down 0.07, from 1 in 2016Q3. It dived, as 24 investors sold PDL BioPharma Inc shares while 59 reduced holdings. 27 funds opened positions while 50 raised stakes. 121.99 million shares or 0.93% less from 123.14 million shares in 2016Q3 were reported. The Pennsylvania-based Janney Montgomery Scott Ltd Liability Co has invested 0% in PDL BioPharma Inc (NASDAQ:PDLI). Amalgamated National Bank & Trust reported 0% stake. Blackrock Advisors Limited Liability holds 86,123 shares or 0% of its portfolio. Rhumbline Advisers stated it has 0% in PDL BioPharma Inc (NASDAQ:PDLI). Mckinley Capital Ltd Limited Liability Company Delaware has 0.03% invested in PDL BioPharma Inc (NASDAQ:PDLI). 1.23M are owned by Goldman Sachs Gru. Moreover, Art Advsrs Ltd Liability Company has 0.02% invested in PDL BioPharma Inc (NASDAQ:PDLI) for 162,900 shares. Americafirst Cap Mgmt Limited Company invested in 60,901 shares. The New York-based D E Shaw Com has invested 0.01% in PDL BioPharma Inc (NASDAQ:PDLI). Qs Investors Ltd Liability has 0% invested in PDL BioPharma Inc (NASDAQ:PDLI). Dimensional Fund Advisors L P reported 0% in PDL BioPharma Inc (NASDAQ:PDLI). Wealthtrust Axiom Ltd Liability holds 0.02% or 30,000 shares. State Street Corp holds 0% or 4.27 million shares. Vanguard Grp reported 13.35M shares. Denali Advsrs Lc holds 0% in PDL BioPharma Inc (NASDAQ:PDLI) or 330 shares.

Among 3 analysts covering PDL BioPharma (NASDAQ:PDLI), 1 have Buy rating, 0 Sell and 2 Hold. Therefore 33% are positive. PDL BioPharma had 6 analyst reports since October 16, 2015 according to SRatingsIntel. The firm earned “Sector Perform” rating on Thursday, November 5 by RBC Capital Markets. The firm has “Sector Perform” rating given on Friday, October 16 by RBC Capital Markets. The rating was maintained by RBC Capital Markets on Tuesday, February 23 with “Sector Perform”. The firm has “Overweight” rating by PiperJaffray given on Thursday, December 22. The rating was maintained by RBC Capital Markets on Tuesday, February 2 with “Sector Perform”.

Since March 24, 2017, it had 1 buying transaction, and 0 insider sales for $49,401 activity. $49,401 worth of PDL BioPharma Inc (NASDAQ:PDLI) was bought by GARCIA PETER S.

PDL BioPharma, Inc. seeks to provide return for its shareholders by acquiring and managing a portfolio of companies, products, royalty agreements and debt facilities in the biotechnology, pharmaceutical and medical device industries. The company has market cap of $390.38 million. The Company’s divisions include income generating assets and product sales. It has a 26.53 P/E ratio. The income generating assets segment consists of royalties from issued patents in the United States and elsewhere, covering the humanization of antibodies, which it refers to as the Queen et al. patents; notes and other long-term receivables, royalty rights-at fair value and equity investments.

Investors sentiment increased to 0.94 in 2016 Q4. Its up 0.01, from 0.93 in 2016Q3. It improved, as 69 investors sold MET shares while 359 reduced holdings. 122 funds opened positions while 279 raised stakes. 810.29 million shares or 2.96% more from 786.98 million shares in 2016Q3 were reported. Eagle Asset Inc invested 0.03% in Metlife Inc (NYSE:MET). Btc Cap Mngmt holds 66,175 shares. Franklin reported 0.7% in Metlife Inc (NYSE:MET). Freestone Ltd Liability Com owns 19,969 shares for 0% of their portfolio. Wright Investors Serv Inc has 0.91% invested in Metlife Inc (NYSE:MET) for 38,915 shares. Amalgamated Comml Bank invested 0.16% of its portfolio in Metlife Inc (NYSE:MET). Thomas J Herzfeld Advsr Inc owns 1,040 shares. Illinois-based Old Republic has invested 1.13% in Metlife Inc (NYSE:MET). Aviva Public Limited Co owns 596,440 shares for 0.19% of their portfolio. Cetera Advisor Networks Lc holds 6,318 shares or 0.02% of its portfolio. Korea Invest reported 0.1% in Metlife Inc (NYSE:MET). Ronna Sue Cohen reported 2.61% stake. Spears Abacus Advsrs Limited Liability Corporation owns 584,027 shares for 4.04% of their portfolio. Blackrock Investment Ltd Liability Corp has invested 0.26% in Metlife Inc (NYSE:MET). Netherlands-based Robeco Institutional Asset Management Bv has invested 0.26% in Metlife Inc (NYSE:MET).

Cowen Group Inc increased New York Reit Inc (NYSE:NYRT) stake by 434,931 shares to 504,931 valued at $5.11M in 2016Q4. It also upped Intersil Corp (NASDAQ:ISIL) stake by 61,925 shares and now owns 402,525 shares. Wisdomtree Tr (Call) (HEDJ) was raised too.

Among 13 analysts covering MetLife (NYSE:MET), 8 have Buy rating, 1 Sell and 4 Hold. Therefore 62% are positive. MetLife had 28 analyst reports since July 31, 2015 according to SRatingsIntel. RBC Capital Markets maintained the shares of MET in report on Monday, June 5 with “Buy” rating. The firm earned “Buy” rating on Monday, January 23 by Deutsche Bank. The rating was maintained by Wells Fargo on Wednesday, June 28 with “Buy”. The stock of Metlife Inc (NYSE:MET) has “Buy” rating given on Wednesday, April 19 by Wells Fargo. The firm earned “Equal-Weight” rating on Wednesday, November 11 by Morgan Stanley. The firm earned “Outperform” rating on Monday, August 29 by FBR Capital. The firm earned “Buy” rating on Monday, July 10 by RBC Capital Markets. The firm earned “Outperform” rating on Friday, September 23 by Wells Fargo. On Friday, May 5 the stock rating was maintained by Wells Fargo with “Buy”. The rating was initiated by Citigroup with “Sell” on Thursday, January 26.

Analysts await Metlife Inc (NYSE:MET) to report earnings on August, 2 after the close. They expect $1.27 earnings per share, up 53.01% or $0.44 from last year’s $0.83 per share. MET’s profit will be $1.36 billion for 10.87 P/E if the $1.27 EPS becomes a reality. After $1.46 actual earnings per share reported by Metlife Inc for the previous quarter, Wall Street now forecasts -13.01% negative EPS growth.

- Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.